TAR 003
Alternative Names: TAR-003Latest Information Update: 28 Jul 2026
At a glance
- Originator TargImmune Therapeutics
- Class Antineoplastics; Polyethylene glycols; RNA
- Mechanism of Action Apoptosis stimulants; Cytokine stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Cervical cancer; Gastric cancer
Most Recent Events
- 28 Jul 2026 No recent reports of development identified for research development in Breast-cancer in Switzerland (Parenteral, Injection)
- 28 Jul 2026 No recent reports of development identified for research development in Cervical-cancer in Switzerland (Parenteral, Injection)
- 28 Jul 2026 No recent reports of development identified for research development in Gastric-cancer in Switzerland (Parenteral, Injection)